about
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malariaCoartem: the journey to the clinicAntimalarial drug resistancePrimaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmissionPrimaquine or other 8-aminoquinoline for reducing P. falciparum transmissionPrimaquine for reducing Plasmodium falciparum transmissionPrimaquine for reducing transmission of Plasmodium falciparum malariaAssessment of the pharmacodynamic properties of antimalarial drugs in vivoMultiple dose study of interactions between artesunate and artemisinin in healthy volunteersOptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimensAdherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.Immunity as a predictor of anti-malarial treatment failure: a systematic reviewAntimalarial bioavailability and disposition of artesunate in acute falciparum malaria.Spiroindolone KAE609 for falciparum and vivax malaria.Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of Candida species.Antimalarial drug resistance and combination chemotherapy.Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malariaIs quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?Efficacy of intramuscular amopyroquin for treatment of Plasmodium falciparum malaria in the Gabon Republic.Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight rangesChemotherapy of drug-resistant malariaMonitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010.Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics.Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Chemical stability of artesunate injection and proposal for its administration by intravenous infusion.Recurrence of Plasmodium falciparum after treatment with quinine and doxycycline in the Amazon basin.Pharmacokinetic interactions between primaquine and chloroquine.Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolismSulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.Chloroquine poisoning: report of two cases.Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.
P2860
Q17485067-35B3A40B-1ED0-4DC2-A5D0-6D6749F30A91Q21034131-C4591BED-0408-4F55-9FE9-DCE6AFE01DE5Q22061790-F3E2CEDB-457B-4979-BCD2-532F3ADB5B85Q24188070-9A4572A6-1E95-42EE-870A-1404D53EF3FCQ24193716-0E8DD728-6645-47FD-AD78-972F56EDB3A8Q24200471-692B853D-D241-4988-A6C4-EDA92C562BC9Q24241596-C74D09F7-251E-4688-9D35-66000C6C5F7FQ24670346-C473EAE0-E5C6-400F-84E0-33915E959900Q28362543-3B4463D5-9B27-4CE5-8F9B-8A73225B2078Q28831110-707E7D3E-56B4-4E90-8A96-1383F5DFFE59Q30397022-B7755F6B-FD59-46C6-BA0E-05DFB70D61DAQ33582154-FFD60BB4-7739-40B2-A3E3-A6B425FD99F1Q33979153-80DE1E43-7794-4FED-A7B8-530C7D8326FBQ34085717-95F08374-7B3F-41F3-978E-A78848135171Q35065737-FE1580A1-9C96-4E01-A0DE-4ECF94F2F149Q35105804-F23EEA68-2A34-44D1-8006-8FA6B691C88BQ35212414-E506DD08-96A2-46E2-9DDD-879878E4E6EAQ35357583-BFDF411F-E463-43B6-9A8C-964562135B74Q35804217-F8D8B734-B511-42E5-BA1D-D5EA73C18A14Q35814071-2AE1140C-7DDB-4584-99B1-F43FCE746858Q35834482-79D88602-2012-4C0F-9A02-57B86EE483E3Q35891386-F7D6B907-A8E6-47FC-A183-3C2659AF4334Q36474415-0F13E3D7-DEBB-4155-B0BE-2788D8CCBFA6Q37979631-96433B35-A9E7-491D-BBB6-82483F13719CQ38082548-E541270A-795E-43BA-8002-81BC3B61E163Q38897136-E71C4EE1-EF60-461B-BDD7-B2B1C054C79BQ39027300-98BC1E52-DC44-4483-9FA7-49FD58378994Q39370895-B52D57A0-0287-4327-AED9-B77CBA5BCE7FQ39465436-3A795CF9-8777-4843-B09F-13325BF60C46Q39792613-27A414CE-5993-4FFF-92A2-20182095C99DQ40579290-7527E983-AFAD-4700-A632-1B655A8030CFQ41921131-9DEFFEA8-C39F-4A1D-B631-8EF2D5DA02E5Q44438917-6AEDE7CF-0230-4A82-B0F4-3437A49BF5D0Q47995484-87383F12-DEC5-42ED-BB0D-E37F5EC5DA42Q48024114-8E983D60-7379-4E96-AC76-CEF01592A0BEQ50052786-1C486755-F25B-4211-9ABF-EFE66FDA08A9
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Antimalarial pharmacokinetics and treatment regimens.
@ast
Antimalarial pharmacokinetics and treatment regimens.
@en
Antimalarial pharmacokinetics and treatment regimens.
@nl
type
label
Antimalarial pharmacokinetics and treatment regimens.
@ast
Antimalarial pharmacokinetics and treatment regimens.
@en
Antimalarial pharmacokinetics and treatment regimens.
@nl
prefLabel
Antimalarial pharmacokinetics and treatment regimens.
@ast
Antimalarial pharmacokinetics and treatment regimens.
@en
Antimalarial pharmacokinetics and treatment regimens.
@nl
P2860
P1476
Antimalarial pharmacokinetics and treatment regimens.
@en
P2860
P356
10.1111/J.1365-2125.1992.TB04100.X
P407
P577
1992-07-01T00:00:00Z